MABTAS RA - 500MG Applepharmaceutical
DESCRIPTION :Mabtas RA 500mg is an anticancer medicine which prevents the growth and spread of cancer cells in the body.
Mabtas RA 500mg will help to prevent the Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for rheumatoid arthritis symptoms in adult treatment.
Mabtas RA 500mg inj with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.
INDICATIONS :
Mabtas RA 500mg inj and hyaluronidase human injection are given alone or combination with otherdrugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).
Mabtas RA 500mg inj injection combination with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also indicated for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen knowns as tumor necrosis factor (TNF) inhibitor. Mabtas RA 500mg is a type in a classification of drugs called monoclonal antibodies.
Mabtas RA 500mg is used to killing cancer cells to treat NHL , CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by inhibiting the activity of the immune system parts that can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.
DOSAGE :
Mabtas RA injection is usually used to administrate only via intravenous infusion not by IV push or bolus.
Before Each Infusion the Drug Is Premediate :
First infusion:
Starting treatment rate of 50 mg/hr. is administer, in not showing infusion toxicity, rate raised up to 50 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.
Successive infusion:
initial at rate of 100 mg/hr., in not showing infusion toxicity, rate raised up to 100 mg/hr. increments at intervals of 30 min and max of 400 mg/hr.While combination with CHOP chemotherapy the injection Mabtas RA has not been given. Hence Premedication with corticosteroids must be considered.
Low grade or follicular non-Hodgkin’s lymphoma:
The drug Dose is 375 mg/m2 as an IV infusion.
Once weeks for 4 or 8 doses administrated for Relapsed treatment
Once weekly for 4 doses administrated for Retreatment for relapsed.
 |
| Mabtas RA 500mg inj |
Previously untreated:
administer on day 1 of each cycle of chemotherapy, up to 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas RA 500mg in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent.
Once weekly for 4 doses at intervals of 6 months and max of 16 doses for Non – progression (following CVP chemotherapy completion 6 – 8 cycles):
On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse Large B- cell NHL
Chronic Lymphocytic Leukemia :
Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.
Component of Zevalin for treatment of NHL:
The dose 250 mg/m2 of Mabtas RA injection within 4 hours prior to the administration of Indium-111-(In-111-) Zevalin and Yttrium-90- (Y-90-) Zevalin.
7–9 days before to Rituxan and Y-90- Zevalin administrate Rituxan and In-111-Zevalin.
Rheumatoid Arthritis:
When combination of Mabtas RA injection with methotrexate is administrated.
Mabtas RAinjection given as two doses of 100mg IV infusion 2 weeks separated.
When glucocorticoids administered as methylprednisolone 100mg IV
Subsequent course based on clinical evaluation must administer every 24 weeks, but not early than every 16 weeks.
Granulomatosis Polyangiitis And Microscopic Polyangiitis :
Mabtas RA injection administer Dose of 375 mg/m2 IV infusion weekly once for 4 weeks.
When Glucocorticoids given with methylprednisolone by dose of 1000 mg IV/ day for 1- 3 days and purse by oral prednisone 1 mg/kg/day are recommended for the treatment of symptoms of serious vacuities This drug should initiate within 14 days before or with the starting of Mabtas RAinjection and may continue during and after the 4-week course with treatment of Mabtas RAinjection drug.
Safety and not established for subsequent infusion.
ADMINISTRTION :
Take an amount Mabtas RAinjection is administer and diluted to final concentration of 1 mg/ml up to 4 mg/ml as infusion (containing either 0.9% Nacl or 5% dextrose in water). Gently Invert the bag and mix the solution. Discard unused drug left in vial.
OVERDOSAGE:
If over dose occurs seek immediately to the emergency department or poison control help line.
please consult the doctor for further clarification.
DRUG INTERACTION
Mabtas RA 500mg drug interaction has limited data is available at present.
Interaction with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients.
Mabtas RA combination with methotrexate had no effects in pharmacokinetics.
CONTRAINDICATION
Hypersensitivity or murine proteins.
Active severe infections in rheumatoid arthritis
Uncontrolled cardiac disease.
MISSED DOSE
If a dose missed then have the drug soon you remembered, if next dose time reach then leave the missed dose and follow the normal schedule.
Do not have 2 doses at a same time. Please consult with doctor for further details.
SIDE EFFECTS
Common effects: fever and chills (flu lik symptoms)
Less common side effects: Weakness; nausea ; headache; cough ; dyspnea ; pharyngitis.
Phone :+91-9987711567Email :
applepharmaceutical@gmail.com
Email :
info@myapplepharma.com
0091-9987711567
No comments:
Post a Comment